Alzheimer's And Aducanumab: Should Taxpayer Money Be Spent?

Alzheimer's And Aducanumab: Should Taxpayer Money Be Spent?

One phase 3 trial succeeded, showing a reduction in the clinical decline standard that defines Alzheimer's, while the second of the two phase 3 trials did not. A reduction in amyloid plaque should mean reduction in clinical decline, based on beliefs about Alzheimer's in the last 100 years. Though everyone agrees Alzheimer's is poorly understood, plaque is the best proxy known right now.How much is that potential benefit worth? A new Hastings Center Report says it's not worth billions of dollars in taxpayer funding. An Obama administration FDA Advisory Panel not only said flibanserin - female viagra - should be approved , they lobbied for it.

About Us

When you want to outsmart the world, you turn to the facts. And the facts are in the science.

Subscribe to our newsletter!